A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients

An Open-label, Cross-over Study, to Compare the PET and SPECT Measurement of Antipsychotic-induced D2 Receptor Occupancy, in a Group of Healthy Volunteers and in Another Group of Patients With Schizophrenia and Other Psychotic Disorders

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00392743

Enrollment

Registered

2006-10-26

Start date

2006-12-31

Completion date

2007-05-31

Last updated

2012-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Bolus, 11C-Raclopride, Schizophrenia, 123I-IBZM, SPECT, Receptor Occupancy, PET, MRI, Antipsychotics, Bolus/Infusion

Brief summary

A direct comparison of Positron Emission Tomography (PET) (11C-Raclopride) and Single Photon Emission Computed Tomography (SPECT) (123I-IBZM) D2 RO measurements would allow GSK to gain understanding on the SPECT results obtained with SB773812, and to accurately interpret future D2 RO results from either PET or SPECT studies with new compounds.

Interventions

PROCEDUREpet/spect scan

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Not pregnant or becoming pregnant during the study. * No abnormality in clinical examination, clinical laboratory test or ECG. * Not taking drugs * Patients with schizophrenia, schizophreniform disorder or schizoaffective disorders. * Patients with at least 1 month antipsychotic monotherapy with either risperidone, olanzapine or clozapine. * Healthy volunteers with no neurological or psychiatric illness.

Exclusion criteria

* Have received other antipsychotic during the last month or neuroleptics during the last year. * If you have taken part in investigations you should not receive a radiation dose of more than 10 mSv over any 3 year period. * History of bleeding disorder or are taking medication that affects blood clotting * History of substance dependence (except nicotine) * Claustrophobia * Gross head deformity. * Unable to lie still in the PET or SPECT camera for 1 hour and a half. * The presence of a cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies.

Design outcomes

Primary

Measure	Time frame
PET and SPECT striatal binding potential	at day 1

Secondary

Measure	Time frame
plasma concentrations at the time of scanning,	at day 1

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026